Fresh from announcing that Hans Schikan, ex-CEO of Prosensa, would be joining the Board of Directors at Wilson Therapeutics, the company have announced the appointment of another Genzyme allumni, Dr. Carl Bjartmar as chief medical officer (CMO). Dr. Bjartmar will report to Jonas Hansson, chief executive officer, and will join the company’s management team.
“We are pleased to welcome Carl to Wilson Therapeutics,” said Jonas Hansson. “We believe that Carl’s extensive expertise within the development of novel therapies for rare diseases will be a tremendous asset to the company to help us reach our goal of developing new treatments for this serious and devastating disease.”
Dr. Bjartmar has extensive experience in clinical drug development with 13 years in pharmaceutical industry. He has been global medical and scientific lead for neurology and neuromuscular programs, including rare diseases. Dr. Bjartmar has directed numerous large and small international studies, and served as sponsor member of study steering committees. He has authored more than 25 international publications, including peer-reviewed articles, review articles and book chapters.
Dr. Bjartmar joins Wilson Therapeutics from Genzyme, a Sanofi Company, where he had roles leading clinical development of treatments for rare and neurological disorders. Prior to Genzyme, Dr. Bjartmar held positions in Clinical Development, Neurology, at Lundbeck A/S, Denmark. Dr. Bjartmar received his Medical and PhD Degrees at the University of Linkoping, Sweden. Between 1998 and 2002 he was a Postdoctoral Fellow at the Department of Neurosciences, Cleveland Clinic Foundation, OH, USA